Several studies highlight the potential utility of miRNAs as biomarkers in either tissues or blood for the assessment of response to the agents implemented in CRC, including the 5-fluorouracil based therapies, and EGFR inhibitors. Here, EGFR is linked to colorectal carcinoma.